clinical trial

[Vor Biopharma] Vor Biopharma, a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer, announced the formation of a collaboration with Janssen Biotech, Inc.

[Children’s Hospital of Philadelphia] The FDA has accepted a new drug application for palovarotene, a drug identified by researchers at Children’s Hospital of Philadelphia to treat fibrodysplasia ossificans progressiva.

[SAB Biotherapeutics] SAB Biotherapeutics announced that the first participant has been dosed in its Phase IIa clinical trial evaluating the safety and efficacy of SAB-176 in a human challenge study.

[Knight Therapeutics, Inc.] Knight Therapeutics, Inc. announced that Health Canada has approved NERLYNX® in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. The approval was based on results of the global Phase III NALA trial.

[Translational Research in Oncology] Translational Research in Oncology (TRIO) announced enrollment completion in coopERA Breast Cancer, a Phase II clinical trial of giredestrant, an oral selective estrogen receptor degrader that showed encouraging tumour activity both alone and in combination with palbociclib in estrogen-receptor positive metastatic breast cancer patients.

[Direct Biologics LLC] Direct Biologics LLC announced that the FDA has approved the application for a Phase I/II trial under an Investigational New Drug (IND) protocol for the use of ExoFlo™ in the treatment of mild-to-moderate COVID-19. ExoFlo™ is an extracellular vesicle product isolated from human bone marrow MSCs.